Skip to content
The Nexus
DossierENTITY

ACHIEVE-5 trial

Coverage of ACHIEVE-5 trial in the Nexus archive.

Earliest in view: Jun 7 · 20:15 UTCMost recent: Jul 6 · 16:45 UTC
Co-mentioned in this coverage
glycemic controltopic2orforgliprontopic1Foundayotopic1American Diabetes Associationorganization1basal insulintopic1body weighttopic1Orforgliprontopic1type 2 diabetestopic1insulin glarginetopic1MedPage Todayorganization1
Recent coverage
  • HEALTHJul 6 · 16:45 UTCMEDPAGE TODAY
    Oral GLP-1 Drug May Simplify Diabetes Treatment

    The ACHIEVE-5 trial demonstrated that adding oral orforglipron (Foundayo) to basal insulin improved glycemic control and reduced body weight in diabetes patients. The results were presented at the American Diabetes Association annual meeting.

  • HEALTHJun 7 · 20:15 UTCMEDPAGE TODAY
    Add-On Orforglipron: Good News for Type 2 Diabetes and Inadequate Glycemic Control

    Once-daily orforglipron improved outcomes in adults with type 2 diabetes and inadequate glycemic control, according to the ACHIEVE-5 trial. The drug is an add-on treatment for patients already on insulin glargine.

ACHIEVE-5 trial · Dossier · The Nexus